Teduglutide Patent Expiration
Teduglutide is Used for treating adult patients with short bowel syndrome who depend on parenteral support. It was first introduced by Takeda Pharmaceuticals Usa Inc
Teduglutide Patents
Given below is the list of patents protecting Teduglutide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gattex Kit |
US7847061 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9060992 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9539310 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9545434 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9545435 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9555079 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9572867 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9592273 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9592274 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9968655 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9968656 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9968658 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9974835 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9974837 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9981014 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9981016 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9987334 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9987335 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit |
US9993528 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity | May 01, 2026 | Takeda Pharms Usa |
| Gattex Kit | US7847061 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9060992 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9539310 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9545434 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9545435 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9555079 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9572867 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9592273 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9592274 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9968655 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9968656 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9968658 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9974835 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9974837 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9981014 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9981016 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9987334 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9987335 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit | US9993528 | Treatment of short bowel syndrome patients with colon-in-continuity | Nov 01, 2025 | Takeda Pharms Usa |
| Gattex Kit |
US7056886 (Pediatric) | GLP-2 formulations |
Mar 18, 2023
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US7056886 | GLP-2 formulations |
Sep 18, 2022
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US5789379 (Pediatric) | Glucagon-like peptide-2 analogs |
Oct 14, 2020
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US5789379 | Glucagon-like peptide-2 analogs |
Apr 14, 2015
(Expired) | Takeda Pharms Usa |
Teduglutide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List